--- title: "Royalty Pharma PLC - CL | 8-K: FY2026 Q1 Revenue: USD 631 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285368181.md" datetime: "2026-05-06T11:34:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285368181.md) - [en](https://longbridge.com/en/news/285368181.md) - [zh-HK](https://longbridge.com/zh-HK/news/285368181.md) --- # Royalty Pharma PLC - CL | 8-K: FY2026 Q1 Revenue: USD 631 M Revenue: As of FY2026 Q1, the actual value is USD 631 M. EPS: As of FY2026 Q1, the actual value is USD 0.53. EBIT: As of FY2026 Q1, the actual value is USD 657 M. #### Revenue and Receipts - Royalty Pharma plc’s Portfolio Receipts increased by 10% to $925 million for the first quarter of 2026, up from $839 million in the first quarter of 2025. - Royalty Receipts grew 13% to $887 million in the first quarter of 2026, compared to $788 million in the first quarter of 2025, driven mainly by Tremfya, Voranigo, and Evrysdi, partially offset by a decline from Promacta due to U.S. generic competition. - Milestones and other contractual receipts were $38 million in the first quarter of 2026, a -25% change from $51 million in the first quarter of 2025. - Total income and other revenues were $631 million for the first quarter of 2026, compared to $568 million for the first quarter of 2025. #### Net Income - Consolidated net income was $468 million for the first quarter of 2026, an increase from $434 million for the first quarter of 2025. - Net income attributable to Royalty Pharma plc was $295 million for the first quarter of 2026, up from $239 million for the first quarter of 2025. #### Operating Expenses and Income - Total operating expense, net was $68 million for the first quarter of 2026, compared to $34 million for the first quarter of 2025. - Operating income was $563 million for the first quarter of 2026, an increase from $534 million for the first quarter of 2025. - Payments for operating and professional costs were -$36 million for the first quarter of 2026, a decrease from -$102 million in the first quarter of 2025. - Financial royalty asset impairment charges were $69 million in the first quarter of 2026, related to Tazverik. #### Cash Flow - Net cash provided by operating activities was $718 million for the first quarter of 2026, an increase of 20% from $596 million in the first quarter of 2025. - Net cash used in investing activities was -$478 million for the first quarter of 2026, compared to $504 million provided by investing activities in the first quarter of 2025. - Net cash used in financing activities was -$273 million for the first quarter of 2026, compared to -$941 million in the first quarter of 2025. #### Non-GAAP Metrics - Adjusted EBITDA increased by 21% to $889 million in the first quarter of 2026, from $738 million in the first quarter of 2025. - Portfolio Cash Flow increased by 18% to $722 million in the first quarter of 2026, from $611 million in the first quarter of 2025. - Capital Deployment was -$528 million in the first quarter of 2026, compared to -$101 million in the first quarter of 2025. #### Balance Sheet and Other Metrics - Cash and cash equivalents stood at $586 million as of March 31, 2026, down from $619 million as of December 31, 2025. - Total debt with principal value was $9.2 billion as of March 31, 2026. - Weighted average Class A ordinary shares outstanding - diluted decreased by 4% to 557 million for the first quarter of 2026, from 578 million for the first quarter of 2025. - Royalty Pharma plc repurchased approximately 1.1 million Class A ordinary shares for $50 million in the first quarter of 2026. - A quarterly dividend of $0.235 per share was paid, totaling $136 million in dividends and distributions in the first quarter of 2026. - The company acquired three royalties for $1.25 billion in announced value during the first quarter. #### Outlook / Guidance - Royalty Pharma plc raised its full year 2026 guidance for Portfolio Receipts to between $3,325 million and $3,450 million, representing an expected Royalty Receipts growth of 4% to 8%. - Payments for operating and professional costs are anticipated to decrease as a percentage of Portfolio Receipts in 2026 compared to 2025, primarily due to the extinguishment of the management fee. - Total interest paid is projected to be approximately $350 million to $360 million for the full year 2026, assuming no additional debt financing. ### Related Stocks - [RPRX.US](https://longbridge.com/en/quote/RPRX.US.md) ## Related News & Research - [Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation | RPRX Stock News](https://longbridge.com/en/news/283538583.md) - [Royalty Pharma PLC $RPRX Shares Bought by Robeco Institutional Asset Management B.V.](https://longbridge.com/en/news/271921142.md) - [West Pharma amends 8-K on material cyberattack disclosure](https://longbridge.com/en/news/287111623.md) - [Colgate-Palmolive Webcasts Fireside Chat at the dbAccess Global Consumer Conference | CL Stock News](https://longbridge.com/en/news/287075346.md) - [ZAWYA: MAAIA accelerates construction progress across La Clé and La Vue, reaffirms Q2 2027 handover](https://longbridge.com/en/news/286406997.md)